Who
David L. Mahoney
Director
Company insider
Files Form 4 as: Director, Corcept Therapeutics; Director, Adamas Pharmaceuticals; Director, Gen Digital; Director, Tercica.
In numbers
- Trades disclosed
- 209
- Buys
- 10
- Sells
- 16
- Bought
- $1.5M
- Sold
- $33.1M
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 17 Feb 2006
- Last trade
- 18 Aug 2026
- Last filed
- 20 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Aug 2026filed 20 Aug 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $585K4,984 at $117.47 | filing |
| 18 Aug 2026filed 20 Aug 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $10.8M91,167 at $118.24 | filing |
| 18 Aug 2026filed 20 Aug 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $839K7,055 at $118.88 | filing |
| 18 Aug 2026filed 20 Aug 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $48K400 at $119.64 | filing |
| 18 Aug 2026filed 20 Aug 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $585K4,984 at $117.47 | filing |
| 18 Aug 2026filed 20 Aug 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $10.8M91,167 at $118.24 | filing |
| 18 Aug 2026filed 20 Aug 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $839K7,055 at $118.88 | filing |
| 18 Aug 2026filed 20 Aug 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $48K400 at $119.64 | filing |
| 17 Jun 2026filed 18 Jun 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $1.7M20,000 at $84.53 | filing |
| 17 Jun 2026filed 18 Jun 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $1.7M20,000 at $84.53 | filing |
| 21 May 2026filed 26 May 2026 | CORT Corcept Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 21 May 2026filed 26 May 2026 | CORT Corcept Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 13 Mar 2026filed 17 Mar 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Code M | $176K30,000 at $5.86 | filing |
| 13 Mar 2026filed 17 Mar 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Code F | $176K5,469 at $32.15 | filing |
| 13 Mar 2026filed 17 Mar 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Code G | —24,531 at $0.00 | filing |
| 13 Mar 2026filed 17 Mar 2026 | CORT Corcept Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —30,000 at $0.00 | filing |
| 13 Mar 2026filed 17 Mar 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Code J | —24,531 at $0.00 | filing |
| 13 Mar 2026filed 17 Mar 2026 | CORT Corcept Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —30,000 at $0.00 | filing |
| 13 Mar 2026filed 17 Mar 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Code M | $176K30,000 at $5.86 | filing |
| 13 Mar 2026filed 17 Mar 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Code F | $176K5,469 at $32.15 | filing |
News
Corcept Therapeutics (NASDAQ:CORT) Stock Falls 14.5% – Should You Sell?CORT · themarketsdaily.com · 23 Oct 2026Corcept Therapeutics (NASDAQ:CORT) vs. Ovid Therapeutics (NASDAQ:OVID) Head-To-Head ContrastCORT · themarketsdaily.com · 15 Oct 2026
0 headlines in the last 90 days name David L. Mahoney; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.